Carpenter Technology (NYSE:CRS) and Mainz Biomed (NASDAQ:MYNZ) Financial Review

Mainz Biomed (NASDAQ:MYNZ) and Carpenter Technology (NYSE:CRS) are both industrials companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, valuation, analyst recommendations and dividends.

Institutional & Insider Ownership

92.0% of Carpenter Technology shares are owned by institutional investors. 18.2% of Mainz Biomed shares are owned by company insiders. Comparatively, 2.9% of Carpenter Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and recommmendations for Mainz Biomed and Carpenter Technology, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mainz Biomed	1	1	0	0	1.50
Carpenter Technology	0	2	8	0	2.80

Carpenter Technology has a consensus target price of $577.25, suggesting a potential upside of 41.53%. Given Carpenter Technology’s stronger consensus rating and higher probable upside, analysts plainly believe Carpenter Technology is more favorable than Mainz Biomed.

Earnings & Valuation

This table compares Mainz Biomed and Carpenter Technology”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mainz Biomed	$659,935.00	18.95	-$21.65 million	($65.60)	-0.02
Carpenter Technology	$3.12 billion	6.47	$529.80 million	$10.52	38.77

Carpenter Technology has higher revenue and earnings than Mainz Biomed. Mainz Biomed is trading at a lower price-to-earnings ratio than Carpenter Technology, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mainz Biomed and Carpenter Technology’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mainz Biomed	N/A	N/A	N/A
Carpenter Technology	16.96%	26.46%	15.02%

Volatility & Risk

Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500. Comparatively, Carpenter Technology has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Summary

Carpenter Technology beats Mainz Biomed on 12 of the 14 factors compared between the two stocks.

About Mainz Biomed

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

About Carpenter Technology

Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves to aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.